RE: RE: 5% of global net sale for 10 years CS. I thought the same about P3A also until I found the Endo was the sponsor for that trial also as disclosed in https://clinicaltrials.gov/show/NCT00406068. That's why I concluded Endo owns results on both P3A and P3B and BNC had to pay them a royalty to buy back the right to use them in my "Endo owns bot P3a and P3B results" post.
But it doesn't really matter now. I agree with you. WHEN is not soon enough for us? I really hope HC would not reuire as large a data pool as FDA for the NOC/c.
On the other hand, at first, when I saw 5%. I was thinking that's a pretty good indication of Endo's confidence in Urocidin. They need only 5% to recoup their spending on Urocidin? But then I have to ask, at this point, what other option does Endo have? Either get whatever BNC offer them for the data or hold on to them and get nothing out of the $36M they have spent. It is already clear that they won't get through FDA with what they have. And with Endo as a partner, HC will not be ver cooperative.
BTW, should we all chip in to bay those bubbling fools at BNC a GPS so they can fine the HC campus?